The ability of bilirubin in identifying smokers with higher risk of lung cancer: A large cohort study in conjunction with global metabolomic profiling

Clinical Cancer Research

Volumn 21, Issue 1, 2015, Pages 193-200

  Wen, Chi Pang ^a,b   Zhang, Fanmao ^c   Liang, Dong ^d   Wen, Christopher ^e   Gu, Jian ^c   Skinner, Heath ^c   Chow, Wong Ho ^c   Ye, Yuanqing ^c   Pu, Xia ^c   Hildebrandt, Michelle A T ^c   Huang, Maosheng ^c   Chen, Chien Hua ^f   Hsiung, Chao Agnes ^a   Tsai, Min Kuang ^a   Tsao, Chwen Keng ^g   Lippman, Scott M ^h   Wu, Xifeng ^c  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d TEXAS SOUTHERN UNIVERSITY   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f SHOW CHWAN MEMORIAL HOSPITAL   (Taiwan)

^g MJ Health Management Institution   (Taiwan)

^h UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; BIOLOGICAL MARKER; LAMBDA GLUTAMYLALANINE; UNCLASSIFIED DRUG; TUMOR MARKER;

ADULT; ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RISK; CASE CONTROL STUDY; CAUCASIAN; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HIGH RISK POPULATION; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; METABOLOMICS; MIDDLE AGED; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; SMOKING; TAIWANESE; VALIDATION STUDY; YOUNG ADULT; AGED; BLOOD; COHORT ANALYSIS; ISOLATION AND PURIFICATION; LUNG TUMOR; MORTALITY; PATHOLOGY;

ADULT; AGED; BILIRUBIN; BIOMARKERS, TUMOR; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; METABOLOMICS; MIDDLE AGED; RISK FACTORS; SMOKING;

EID: 84920687427     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-0748     Document Type: Article

References (30)

1. Wender R, Fontham ET, Barrera E Jr, Colditz GA, Church TR, Ettinger DS, et al. American Cancer Society lung cancer screening guidelines. CA Cancer J Clin 2013;63:107-17.
2. Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011;365:395-409.
3. Bach PB, Mirkin JN, Oliver TK, Azzoli CG, Berry DA, Brawley OW, et al. Benefits and harms of CT screening for lung cancer: a systematic review. JAMA 2012;307:2418-29.
4. Wood DE, Eapen GA, Ettinger DS, Hou L, Jackman D, Kazerooni E, et al. Lung cancer screening. J Natl Compr Cancer Netw 2012;10:240-65.
5. Jaklitsch MT, Jacobson FL, Austin JH, Field JK, Jett JR, Keshavjee S, et al. The American Association for Thoracic Surgery guidelines for lung cancer screening using low-dose computed tomography scans for lung cancer survivors and other high-risk groups. J Thorac Cardiovasc Surg 2012;144: 33-8.
6. Kovalchik SA, Tammemagi M, Berg CD, Caporaso NE, Riley TL, Korch M, et al. Targeting of low-dose CT screening according to the risk of lung-cancer death. N Engl J Med 2013;369:245-54.
7. 2020 visions. Nature 2010;463:26-32.
8. Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 2009;457:910-4.
9. Gu H, Pan Z, Xi B, Asiago V, Musselman B, Raftery D. Principal component directed partial least squares analysis for combining nuclear magnetic resonance and mass spectrometry data in metabolomics: application to the detection of breast cancer. Anal Chim Acta 2011;686:57-63.
10. Ritchie SA, Ahiahonu PW, Jayasinghe D, Heath D, Liu J, Lu Y, et al. Reduced levels of hydroxylated, polyunsaturated ultra long-chain fatty acids in the serum of colorectal cancer patients: implications for early screening and detection. BMC Med 2010;8:13.
11. Zhang J, Liu L, Wei S, Nagana Gowda GA, Hammoud Z, Kesler KA, et al. Metabolomics study of esophageal adenocarcinoma. J Thorac Cardiovasc Surg 2011;141:469-75, 75 e1-4.
12. Ikeda A, Nishiumi S, Shinohara M, Yoshie T, Hatano N, Okuno T, et al. Serum metabolomics as a novel diagnostic approach for gastrointestinal cancer. Biomed Chromatogr 2012;26:548-58.
13. Xue R, Lin Z, Deng C, Dong L, Liu T, Wang J, et al. A serum metabolomic investigation on hepatocellular carcinoma patients by chemical derivatization followed by gas chromatography/mass spectrometry. Rapid Commun Mass Spectrom 2008;22:3061-8.
14. Gao H, Dong B, Liu X, Xuan H, Huang Y, Lin D. Metabonomic profiling of renal cell carcinoma: high-resolution proton nuclear magnetic resonance spectroscopy of human serum with multivariate data analysis. Anal Chim Acta 2008;624:269-77.
15. Zhou J, Xu B, Huang J, Jia X, Xue J, Shi X, et al. 1H NMR-based metabonomic and pattern recognition analysis for detection of oral squamous cell carcinoma. Clin Chim Acta 2009;401:8-13.
16. Bathe OF, Shaykhutdinov R, Kopciuk K, Weljie AM, McKay A, Sutherland FR, et al. Feasibility of identifying pancreatic cancer based on serum metabolomics. Cancer Epidemiol Biomarkers Prev 2011;20:140-7.
17. Hori S, Nishiumi S, Kobayashi K, Shinohara M, Hatakeyama Y, Kotani Y, et al. A metabolomic approach to lung cancer. Lung Cancer 2011;74: 284-92.
18. Jordan KW, Adkins CB, Su L, Halpern EF, Mark EJ, Christiani DC, et al. Comparison of squamous cell carcinoma and adenocarcinoma of the lung by metabolomic analysis of tissue-serum pairs. Lung Cancer 2010;68: 44-50.
19. Maeda J, Higashiyama M, Imaizumi A, Nakayama T, Yamamoto H, Daimon T, et al. Possibility of multivariate function composed of plasma amino acid profiles as a novel screening index for non-small cell lung cancer: a case control study. BMC Cancer 2010;10:690.
20. Spitz MR, Hong WK, Amos CI, Wu X, Schabath MB, Dong Q, et al. A risk model for prediction of lung cancer. J Natl Cancer Inst 2007;99:715-26.
21. Wen CP, Cheng TY, Tsai MK, Chang YC, Chan HT, Tsai SP, et al. All-cause mortality attributable to chronic kidney disease: a prospective cohort study based on 462 293 adults in Taiwan. Lancet 2008;371:2173-82.
22. Wen CP, Wai JP, Tsai MK, Yang YC, Cheng TY, Lee MC, et al. Minimum amount of physical activity for reduced mortality and extended life expectancy: a prospective cohort study. Lancet 2011;378:1244-53.
23. Lawton KA, Berger A, Mitchell M, Milgram KE, Evans AM, Guo L, et al. Analysis of the adult human plasma metabolome. Pharmacogenomics 2008;9:383-97.
24. Ryter SW, Morse D, Choi AM. Carbon monoxide and bilirubin: potential therapies for pulmonary/vascular injury and disease. Am J Respir Cell Mol Biol 2007;36:175-82.
25. Lin JP, O'Donnell CJ, Schwaiger JP, Cupples LA, Lingenhel A, Hunt SC, et al. Association between the UGT1A1∗28 allele, bilirubin levels, and coronary heart disease in the Framingham Heart Study. Circulation 2006;114:1476-81.
26. Novotny L, Vitek L. Inverse relationship between serum bilirubin and atherosclerosis in men: ameta-analysis of published studies. Exp Biol Med 2003;228:568-71.
27. Horsfall LJ, Rait G, Walters K, Swallow DM, Pereira SP, Nazareth I, et al. Serum bilirubin and risk of respiratory disease and death. JAMA 2011;305:691-7.
28. O'Malley SS, Wu R, Mayne ST, Jatlow PI. Smoking cessation is followed by increases in serum bilirubin, an endogenous antioxidant associated with lower risk of lung cancer and cardiovascular disease. Nicotine Tob Res 2014;16:1145-9.
29. Frost-Pineda K, Liang Q, Liu J, Rimmer L, Jin Y, Feng S, et al. Biomarkers of potential harm among adult smokers and nonsmokers in the total exposure study. Nicotine Tob Res 2011;13:182-93.
30. How Tobacco Smoke Causes Disease. The biology and behavioral basis for smoking-attributable disease. A Report of the Surgeon General. Atlanta (GA); 2010.